The Number That Should Stop You: Building Continuity Before Big Tech Does, with Amy Andrade

The Number That Should Stop You: Building Continuity Before Big Tech Does, with Amy Andrade

People whose care is scattered across multiple providers, with no single person or system holding the whole picture, have more than double the risk of dying, even after accounting for how sick they already are. Amy Andrade has spent her career on that gap. In this episode of The Clinical Realist, Dr. Sarah Matt talks with Amy Andrade, Co-Founder and Chief Product Officer of Alphiniti and a biomedical data science researcher at Meharry Medical College. Alphiniti is building person-centric data continuity, infrastructure that keeps one person's record connected across health, financial, and legacy systems instead of scattered across every institution they have ever touched. Amy is also an active advisory client, so this conversation flips the mic on a build Sarah has watched from the inside. The conversation covers what continuity looks like as a shipped product rather than a slide in a deck, the split between institutional (B2B) and consumer-facing (B2B2C) buyers, why AI tools built to fix fragmentation can fail silently for the people already falling through the cracks, the middleware critique and where it does and does not hold up, and how a company Alphiniti's size competes for this category before Big Tech, already signaling interest in the same space, claims it. What you will take away: - Why fragmented data carries a measurable mortality cost, not just an inconvenience - What continuity actually means as a product, not a pitch-deck slide - How B2B and B2B2C buyers value the same infrastructure differently - Where the data-continuity-as-middleman critique is fair, and where it isn't - What has to be true for a company like Alphiniti to win this category Find Amy and Alphiniti: alphiniti.com Book a Discovery and Clarity Session: https://calendly.com/sarahmattmd Subscribe to The Sarah Matt Briefing: https://drsarahmatt.com/newsletter-signup — Resources & Links: 📖 Get the Book: "The Borderless Healthcare Revolution" is available now on Amazon and major retailers. 💼 Work with Dr. Matt: Looking for a keynote speaker or strategic advisor? Visit: drsarahmatt.com 🔗 Connect on Social: LinkedIn: https://www.linkedin.com/in/sarahmattmd/ YouTube: https://www.youtube.com/@DrSarahMatt-ClinicalRealist [http://www.youtube.com/@DrSarahMatt] 📧 Subscribe to The Briefing: drsarahmatt.com/newsletter-signup   — Disclaimer: The views expressed on this podcast are those of Dr. Sarah Matt and her guests. They do not necessarily reflect the official policy or position of any affiliated institutions. This content is for informational and educational purposes only and does not constitute medical advice or a professional consulting relationship.

What an Acquirer Is Actually Buying: Exit-Readiness for Healthtech, with Dr. Roxie Mooney

Most healthtech founders solve a real clinical problem, get piloted in a few systems, and then discover that solving the clinical problem was never the same thing as building a company someone would actually buy. Dr. Roxie Mooney, DBA, has spent her career on that exact gap. In this episode of The Clinical Realist, Dr. Sarah Matt talks with Dr. Roxie Mooney, founder and CEO of Legacy DNA, where she works with midmarket healthtech and pharmacy companies, often private-equity backed, who are twelve to thirty-six months out from an acquisition or a capital event. She holds a Doctorate in Business Administration focused on commercializing healthcare technology. She helped scale BioPlus Specialty Pharmacy from roughly 750 million dollars to 2 billion in revenue, which led to back-to-back acquisitions by Nautic Partners and then Elevance Health, and she has been part of four successful exits. The conversation covers what an acquirer is actually buying, why most healthtech companies are commercially unready long before they think they are, pilotitis from the commercialization side, the first metric a strategic acquirer opens the diligence folder to find, where pharma and healthtech commercial logic split, and what the current deal climate means for a company eighteen months from an exit. What you will take away: - What a strategic acquirer is actually buying, beyond the clinical science - The signs a founder does not yet understand what makes a company acquirable - Why pilotitis is the enemy of exit readiness - The first metric in the diligence folder - A clear read on the current M and A climate for healthtech Find Roxie: LinkedIn https://www.linkedin.com/in/roxiemooney/ | Substack https://healthinnovatorsedge.substack.com | Book: How Health Innovators Maximize Market Success | Company: Legacy DNA (https://legacy-dna.com) Book a Discovery and Clarity Session: https://calendly.com/sarahmattmd Subscribe to The Sarah Matt Briefing: https://drsarahmatt.com/newsletter-signup — Resources & Links: 📖 Get the Book: "The Borderless Healthcare Revolution" is available now on Amazon and major retailers. 💼 Work with Dr. Matt: Looking for a keynote speaker or strategic advisor? Visit: drsarahmatt.com 🔗 Connect on Social: LinkedIn: https://www.linkedin.com/in/sarahmattmd/ YouTube: https://www.youtube.com/@DrSarahMatt-ClinicalRealist [http://www.youtube.com/@DrSarahMatt] 📧 Subscribe to The Briefing: drsarahmatt.com/newsletter-signup   — Disclaimer: The views expressed on this podcast are those of Dr. Sarah Matt and her guests. They do not necessarily reflect the official policy or position of any affiliated institutions. This content is for informational and educational purposes only and does not constitute medical advice or a professional consulting relationship.

AI Is a Power Shift, Not Just a Tool: Dr. Robert Pearl on What Generative AI Actually Changes for Physicians and Health Systems

Two years ago, every health system was running an AI pilot. Today, most are still running AI pilots. The technology improved dramatically. The deployment gap between what a board approves and what happens in an exam room stayed the same. In this episode of The Clinical Realist, Dr. Sarah Matt talks with Dr. Robert Pearl about what that gap looks like from inside a system that actually closed it. Pearl was CEO of The Permanente Medical Group and Co-CEO of Kaiser Permanente for 18 years, running 22,000 physicians and 103,000 staff while practicing facial plastic surgery. He is now a clinical professor at Stanford GSB and the School of Medicine, and the author of ChatGPT, MD: How AI-Empowered Patients and Doctors Can Take Back Control of American Medicine. The conversation covers the part that does not fit on a conference slide: the honest before-and-after between narrow AI and generative AI, why patients gaining information parity with physicians is a power shift and not just a convenience, the diagnostic error comparison that almost no one in medicine will make publicly, and what it actually takes to close the boardroom-to-care-floor seam before the tools scale past the governance. What you will take away: - The honest clinical difference between the first wave of narrow AI and generative AI in practice (not in press releases) - Why physician resistance to AI second-opinions is about power structure, not just liability or hallucinations - The diagnostic error comparison between AI and physicians, and why the data is not being discussed publicly - What health system boards are being told about AI ROI versus what is actually happening in exam rooms - Where the governance needs to be before the tools scale Book a Discovery and Clarity Session: https://calendly.com/sarahmattmd Subscribe to The Sarah Matt Briefing: https://drsarahmatt.com/newsletter-signup — Resources & Links: 📖 Get the Book: "The Borderless Healthcare Revolution" is available now on Amazon and major retailers. 💼 Work with Dr. Matt: Looking for a keynote speaker or strategic advisor? Visit: drsarahmatt.com 🔗 Connect on Social: LinkedIn: https://www.linkedin.com/in/sarahmattmd/ YouTube: https://www.youtube.com/@DrSarahMatt-ClinicalRealist [http://www.youtube.com/@DrSarahMatt] 📧 Subscribe to The Briefing: drsarahmatt.com/newsletter-signup   — Disclaimer: The views expressed on this podcast are those of Dr. Sarah Matt and her guests. They do not necessarily reflect the official policy or position of any affiliated institutions. This content is for informational and educational purposes only and does not constitute medical advice or a professional consulting relationship.

Why Health Systems Keep Getting Patient Experience Wrong | Amanda Brummitt, FACHE

Patient experience gets treated as a soft metric. Amanda Brummitt, FACHE, has spent 25+ years in health system operations proving it is a margin lever, a retention lever, and the first thing most AI rollouts ignore.\n\nIn this episode of The Clinical Realist, Dr. Sarah Matt sits down with Amanda Brummitt, Principal of Brummitt Group, to unpack why patient experience is strategy, not sentiment, and what health system leaders get wrong when they bolt AI onto a broken experience.\n\nGuest: Amanda Brummitt, FACHE, Principal, Brummitt Group\nHost: Dr. Sarah Matt, MD, MBA, surgery-trained physician-executive\n\ndrsarahmatt.com | https://calendly.com/sarahmattmd — Resources & Links: 📖 Get the Book: "The Borderless Healthcare Revolution" is available now on Amazon and major retailers. 💼 Work with Dr. Matt: Looking for a keynote speaker or strategic advisor? Visit: drsarahmatt.com 🔗 Connect on Social: LinkedIn: https://www.linkedin.com/in/sarahmattmd/ YouTube: https://www.youtube.com/@DrSarahMatt-ClinicalRealist [http://www.youtube.com/@DrSarahMatt] 📧 Subscribe to The Briefing: drsarahmatt.com/newsletter-signup   — Disclaimer: The views expressed on this podcast are those of Dr. Sarah Matt and her guests. They do not necessarily reflect the official policy or position of any affiliated institutions. This content is for informational and educational purposes only and does not constitute medical advice or a professional consulting relationship.

The Other Side of the Table: What Academic Health Systems Actually Need From Health Tech

Dr. Marschall Runge, MD, PhD, Dean of the University of Michigan Medical School and CEO of Michigan Medicine, sits across the table from health tech founders every day. In this episode, he shares the institutional reality that most health tech companies never see: what it actually takes for an academic medical center to say yes. Not the demo. Not the pilot. The governance questions, the budget structures, the clinical workflow realities, and the leadership calculus that decides whether a tool survives past the first quarter. If you build for health systems, or you are trying to scale inside one, this is the conversation that explains why the buyer behaves the way they do. — Resources & Links: 📖 Get the Book: "The Borderless Healthcare Revolution" is available now on Amazon and major retailers. 💼 Work with Dr. Matt: Looking for a keynote speaker or strategic advisor? Visit: drsarahmatt.com 🔗 Connect on Social: LinkedIn: https://www.linkedin.com/in/sarahmattmd/ YouTube: https://www.youtube.com/@DrSarahMatt-ClinicalRealist [http://www.youtube.com/@DrSarahMatt] 📧 Subscribe to The Briefing: drsarahmatt.com/newsletter-signup   — Disclaimer: The views expressed on this podcast are those of Dr. Sarah Matt and her guests. They do not necessarily reflect the official policy or position of any affiliated institutions. This content is for informational and educational purposes only and does not constitute medical advice or a professional consulting relationship.